The Drug a New Skin-Peptide Review Cites Already Changed Its Name

Experimental Dermatology published a review this month on the roles antimicrobial peptides play in skin cancer, cataloguing molecules like dermcidin, psoriasin, LL-37, RNase-7, and human beta-defensins, native compounds the skin produces to fight off bacteria, fungi, and viruses. The authors, based in the University of South Florida's Department of Dermatology and Cutaneous Surgery and senior-authored by dermatologist James Grichnik, describe how these peptides shape tumor behavior through the skin microbiome, innate immune signaling, and chronic inflammation. Turning to where the science might lead clinically, they name LL-37 and a compound called LTX-315 as candidates worth watching.

The dual nature of skin's own peptides is real, and it has been documented for well over a decade, not a finding this review introduces. LL-37, the skin's most studied cathelicidin, shows up in study after study as both defender and accomplice: it correlates with tumor stage in melanoma, and separate mechanistic work has traced how it activates tumor-associated macrophages and induces VEGF and matrix metalloproteinases, the same signals that let a tumor recruit blood vessels and invade surrounding tissue. Psoriasin behaves similarly, turning up more in actinic keratosis and squamous cell carcinoma than in healthy skin, with no settled answer on whether it is cause, consequence, or bystander.

A candidate that didn't come from skin

LTX-315 is a different story. It is not a human skin peptide at all. Researchers built it by re-engineering lactoferricin, a defense peptide isolated from cow's milk, shortening the chain to nine amino acids and swapping in a bulky synthetic amino acid to sharpen its ability to rupture cancer cell membranes. It works by direct injection into a tumor, not through any mechanism related to the skin's own antimicrobial defenses.

That distinction matters because LTX-315 is also the more clinically advanced of the two candidates the review names, and it has already outgrown the name the review uses for it. Its developer, Norway's Lytix Biopharma, gave it an official nonproprietary name, ruxotemitide, well before this issue went to print. Under that name, injected ruxotemitide combined with pembrolizumab produced durable responses in patients with advanced melanoma who had stopped responding to prior immunotherapy, according to final Phase II results from the completed ATLAS-IT-05 trial, presented at the American Association for Cancer Research meeting in April 2026. A second Phase II study, NeoLIPA, run at Oslo University Hospital with 27 patients, is testing the same combination before surgery in resectable stage III and IV melanoma. Neither trial has produced an approval. Both remain Phase II, measuring durability in a small patient count.

None of this makes the review wrong to mention LTX-315. It makes the label worth checking. A compound's presence in a clinical section does not mean it is derived from the biology the rest of the article describes, and a peptide's name in a given paper may already be a step behind where its own trial registry has moved. Before treating any antimicrobial peptide as a bridge from lab bench to skin clinic, the narrower questions are the useful ones: does this molecule actually come from skin, and under what name, and what phase, is it currently registered.

Sources: PubMed · ClinicalTrials.gov · ClinicalTrials.gov